CPHI Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 15:59):

Stats
Today's Volume	437 586
Average Volume	444 774
Market Cap	4.71M
EPS	$0 ( 2024-04-01 )
Next earnings date	( $0 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.350
ATR14	$0.00400 (1.26%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-28	Liu Tao (chengdu)	Sell	0	Common Stock
2023-09-29	Li Zhilin	Buy	13 757 063	Common Stock
2022-12-30	Deng Ke	Sell	0	Common Stock
2021-09-09	Li Zhilin	Buy	1 760 000	Common Stock
2020-12-23	Li Zhilin	Buy	2 000 000	Common Stock

INSIDER POWER
100.00
Last 33 transactions
Buy: 32 776 034 \| Sell: 18 065 779

Volume Correlation

Long: -0.19 (neutral)

Short: -0.93 (very strong negative)

Signal:(48.138) Neutral

China Pharma Holdings Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

China Pharma Holdings Inc Correlation - Currency/Commodity

-0.61
( weak negative )

-0.82
( strong negative )

0.00
( neutral )

0.35
( neutral )

China Pharma Holdings Inc Financials

Annual	2023
Revenue:	$7.01M
Gross Profit:	$-504 881 (-7.20 %)
EPS:	$-0.910

Q4	2023
Revenue:	$2.15M
Gross Profit:	$-141 416 (-6.58 %)
EPS:	$-0.120

Q3	2023
Revenue:	$1.80M
Gross Profit:	$-233 190 (-12.93 %)
EPS:	$-0.290

Q2	2023
Revenue:	$1.10M
Gross Profit:	$-146 661 (-13.36 %)
EPS:	$-0.300

Financial Reports:

No articles found.

China Pharma Holdings Inc

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. was founded in 1993 and is based in Haikou, the People's Republic of China.